Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2017-04-05 Capital/Financing Update
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 5, 2017, reporting the entry into a material definitive agreement for a registered direct offering of American Depositary Shares (ADSs) by Adaptimmune Therapeutics plc. It includes details about the purchase agreement and references a press release. The content focuses on a financing transaction and capital raising activity. There are no financial statements or comprehensive financial performance data presented, nor is it an earnings release or management discussion. The primary subject is the update on a capital raising event, which fits the Capital/Financing Update category.
2017-04-05 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a registered direct offering of American Depositary Shares (ADSs). It includes detailed information about the offering, risk factors, use of proceeds, and other legal and financial disclosures typical of a prospectus supplement. It is not an annual report, earnings release, or any other type of financial report but rather a capital raising document describing the terms of a securities offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains substantive content about the offering, not just an announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2017-04-05 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 27, 2017. It includes announcements of two main items: an updated corporate presentation and a press release about the closing of an underwritten public offering of American Depositary Shares. The corporate presentation is attached as Exhibit 99.1, and the press release as Exhibit 99.2. The document itself is relatively short (4156 characters) and primarily serves to announce these events and provide the exhibits. There are no detailed financial statements or substantive financial data within the text itself, only references to the attached presentation and press release. The key content is the announcement of a corporate presentation update and a financing event (public offering). Given the nature of the content, the primary focus is on the updated corporate presentation, which is a detailed presentation for investors focusing on financials, strategy, and market position. Therefore, the most appropriate classification is Investor Presentation (IP). The mention of the public offering is secondary and does not constitute a full financing update report but is included in the 8-K as an event. Confidence is high due to clear identification of the corporate presentation and the nature of the filing.
2017-03-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-03-29 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-03-29 English
FORM 4 SUBMISSION
Director's Dealing
2017-03-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.